Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab.

Savino Sciascia,Maria Letizia Antonietta Rilat,Roberta Fenoglio,Silvia Grazietta Foddai,Massimo Radin,Irene Cecchi, Giacoma Cinnirella,Paola Crosasso, Maria Gabriella Guidetti,Alice Barinotti,Simone Baldovino,Elisa Menegatti,Dario Roccatello

Clinical kidney journal（2023）

引用 1|浏览4

暂无评分

摘要

Pre-exposure prophylaxis with tixagevimab/cilgavimab seems safe and lowered the risk of symptomatic SARS-CoV-2 infection by ≈40% in vaccinated subjects with GD who received anti-CD20 therapy. Possible applications in the subset of patients who need immunosuppressive therapy, especially with rituximab, in a pandemic setting might be envisaged.

查看译文

关键词

Evusheld, glomerular diseases, glomerulonephritis, monoclonal antibodies, rituximab, tixagevimab, cilgavimab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要